Platinum-based chemotherapy was previously the first-choice treatment for lung cancer. The
discovery of epidermal growth factor receptor (EGFR) gene mutations and the development …

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review
on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates - PMC …

Epidermal growth factor receptor (EGFR) mutation is one of the key oncogenic mutations in
non-small-cell lung cancer with adenocarcinoma histology. Exon 19 deletions and exon 21 …

Abstract Histone deacetylase 11 (HDAC11) is a unique member of the histone deacetylase
family that plays an important role in the regulation of gene expression and protein function …

Immune checkpoint inhibitors (ICIs) are effective against advanced and even perioperative
non-small-cell lung cancer (NSCLC) and result in durable clinical benefit, regardless of …

Background Data on the use of immune checkpoint inhibitors (ICIs) in advanced non-small
cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation …

Introduction: The activity of immune checkpoint inhibitors (ICIs) in NSCLC harboring EGFR
exon 20 insertion mutations (ex20ins) has not been closely examined due to the frequent …

Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted
non-small-cell lung cancer (NSCLC). RET rearrangements are typically observed in about 1 …

Background Targeted therapies have improved survival and quality of life for patients with
non-small-cell lung cancer with actionable driver mutations. However, epidermal growth …

Introduction Real-world evidence regarding molecular epidemiology and management
patterns of patients with EGFR exon-20 mutated, advanced NSCLC outside the context of …